Novonesis

H1 20: soft guidance takes centre stage

14/08/20 -"Novozymes reported largely in line Q2 20 numbers as sales were down 2% (in line with the trading update) and the EBIT margin came in at 25.9% (-10bp vs trading update). The key takeaway was the ..."

PDF page sample
Pages
51
Language
English
Published on
14/08/20
Download
You may also be interested by these reports :
27/02/26
The Q4 sales exceeded expectations, though ‘adjusted’ EBITDA was somewhat behind the consensus. The Q4 performance was driven by LatAm, Animal ...
26/02/26
Even though the H2 25 results were ahead of consensus, the 2026 outlook was below the street’s expectations. While Branded posted strong H2 growth, ...
26/02/26
Novonesis stumbled at the finish line — Q4 25 revenue and EBITDA missed consensus by 2.3% and 2.9% respectively, dragged down by weakness in the ...
26/02/26
The H2 25 results exceeded the consensus, and the 2026 guidance (CER) was better than the consensus estimates at AER. The H2 performance was driven ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO